The Idea

In 1984, Al Czap was a supplement salesman in Seattle who had stopped believing in what he was selling. He kept turning the bottles over. Binders, fillers, preservatives, flowing agents. Ingredient lists padded with things nobody could explain and the body could not absorb. The people who needed supplements most, patients with severe allergies and wrecked digestion, reacted badly to half of what was in the capsule and got nothing from the rest. The doctors treating them had nowhere to send them.

So Al and his wife Kelly started making their own. One product. Hypoallergenic. No binders, no fillers, capsules formulated so they would not trigger a reaction. No shelf space, no advertising, no retail at all. They sold straight to the physicians who would recommend it by name, serving a channel the rest of the industry ignored because it was small, demanding and slow.

This was the beginning of Thorne.

The Execution

• 1984: Thorne Research launched as a practitioner-only brand out of Seattle with 25 employees and a handful of SKUs, sold exclusively through doctors and pharmacists.
• 1990: Czap moved the operation to Sandpoint, Idaho. By 1997 sales were compounding at an average of 30% a year on 55 staff, and he was turning down European distributors weekly because he had no capacity. His line at the time: steady growth, not uncontrolled growth.
• 2010: Czap stepped back, merging Thorne with Diversified Natural Products in a deal financed by WestView Capital and Tudor Ventures. Paul Jacobson took the CEO seat. Czap kept a minority stake and a consulting role.
• 2018: After 34 years of selling only through practitioners, Thorne opened a direct-to-consumer channel. Two years later, lockdown hit and its zinc picolinate became the breakout seller.
• February 2021: Thorne merged with AI health-intelligence company Onegevity and raised $138.4 million from Mitsui and Kirin at $5.12 a share, rebranding as Thorne HealthTech.
• September 2021: The IPO went badly before it even priced. Thorne cut the deal from 9 million shares at $13 to $15 down to 7 million shares, then priced at $10, the low end of the revised range, raising $70 million at a $525 million valuation.
• July 2023: Public markets had no idea what to do with a supplement company that called itself a health-tech company. The stock sat near $5, roughly half its IPO price. L Catterton's rescue bid of $10.20 a share was a 94% premium to that unaffected close, valuing Thorne at $680 million.
• October 2023: The take-private closed with 97.3% of shares tendered. Thorne delisted from Nasdaq after 25 months as a public company.
• 2023 to 2025: L Catterton installed ex-Vitamin Shoppe boss Colin Watts as CEO and simplified the go-to-market. Revenue more than doubled from $229 million in 2022 to over $500 million in 2025, a 30%-plus CAGR, with the direct customer base growing from 4 million to 7 million and DTC sales up 63% in a single year.
• 4 August 2026: P&G agreed to buy Thorne for $3.8 billion in cash, seeing off a rival bid from Haleon and handing L Catterton a return of more than $3 billion in under three years. Thorne is on pace for $650 million of revenue this year, with 60% of it from shoppers under 40.

The lesson?

Thorne spent 39 years being worth $680 million and three years being worth $3.8 billion. The product barely changed. What changed is that a generation that reads the ingredient list before it buys finally showed up, and the only brand ready for them was the one that had spent four decades refusing shelf space, refusing advertising and selling through doctors who would not stake their name on rubbish. Czap was not building a moat. He was just being fussy. Turns out fussy compounds. The moat you dig when nobody is paying for it is the one somebody eventually pays $3.8 billion for.